Active — Not RecruitingNot Applicable

The Use of Bio-Oss Collagen for Sinus Augmentation Using the Transcrestal Approach.

Israel36 participantsStarted 2020-10-15

Plain-language summary

To assess vertical bone height gain with Geistlich Bio-Oss Collagen used in conjunction with simultaneous implant installation in transcrestal approach sinus augmentation.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients above the age of 18. * Patients with edentulous ridge maximal height of 8mm≥ beneath the maxillary sinus. * Patients with edentulous ridge minimal height of 3mm≤ beneath the maxillary sinus. * Patients who need single implant placement at the posterior maxilla. * Signed, well filled and dated informed consent form. Exclusion Criteria: * Inability to complete or understand the informed consent process. * Pregnant women. * Lactating women. * Patients who use medications that affect bone metabolism such as IV bisphosphonates. * Heavy smokers. * Patients with chronic/acute sinus infections

What they're measuring

Vertical bone height. (mm)Changes in augmented bone after transcrestal approach sinus augmentation.

Timeframe: Pre op; immediately post-op, at 6 months and 3 years from second stage surgery.

Trial details

NCT IDNCT04581304

SponsorRambam Health Care Campus

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-17

View on ClinicalTrials.gov More Bone Loss trials